The Pharmaceutical Market: Colombia

The Pharmaceutical Market: Colombia published by Espicom Business Intelligence in October, 2011. This report consists of Pages: 66 and the price starts from US $ 1085.

Introduction

A stable macroenvironment will make the Colombian pharmaceutical market more attractive. Juan Manuel Santos, who relied on the popularity of Alvaro Uribe, won the run-off presidential race in June 2010. He aims to improve relations with Venezuela and Ecuador, and continue to fight against drug trafficking. Economically, the country has felt some effects from the current global credit crisis, but GDP is expected to grow by a moderate one-digit rate in real terms in 2011, according to the Economist Intelligence Unit (EIU). Legally, the Office of the United States Trade Representative (USTR) has kept Colombia on the Watch List in 2011. Demographically, the country has the third largest population in Latin America, which is an attractive market, but those aged 65 and over only represent less than 6% of the total in 2011, according to the EIU.

Colombian drug prices have been deregulated since 2006, therefore all the players in the distribution channels have abused their power to increase drug prices, particularly affecting drugs not included in the Mandatory Health Plan (POS) or drugs for which there is no competition. The Ministry of Social Protection (MPS) believes that drug pricing deregulation, which has resulted in drugs being overpriced, is one of the causes that explain the financial crisis in the public health sector. In the last decade, thousands of Colombians have used a judicial action for the protection of basic rights (Tutela) and demanded the provision of health services that are excluded from the mandatory health plan (POS); these are known as non-POS services. Nearly 800,000 Tutelas for health services were reported in the 1999-2009 period, equal to a third of the total. Of these, just above 100,000 were recorded in 2009, which represented a fall of 6.3% over 2008.

Colombia has the fourth smallest pharmaceutical market in the Latin America region. The pharmaceutical market is set to expand at a one-digit CAGR in dollar terms between 2011 and 2016. The economic and political environment is stable, therefore the outlook is positive for pharmaceutical market growth. Colombia is looking to increase drug access for the whole population under the universal insurance programme (SGSSS), which should expand the market accordingly. Pharmaceutical imports and exports will increase. The number of pharmaceutical companies operating in the market has also risen. Gross pharmaceutical production will continue its upward trend and the industry is expected to create more employment. The leading pharmaceutical company is Tecnoquimicas, followed by Baxter, Roche, Abbott and Bayer. In February 2011, the Swiss Nycomed announced the acquisition of a local company.

Espicom's highly regarded world pharmaceutical market reports have been redesigned to provide enhanced strategic intelligence in a user-friendly format. Each report provides in-depth information, setting the pharmaceutical market in context.

The reports provide:

• Five-year projections for economic, demographic, health expenditure, health workforce and pharmaceutical market indicators.
• Specialised intelligence on OTCs, generics, biologics and biosimilars.
• Exclusive economic and demographic data from the Economist Intelligence Unit (EIU) for each market in the series.
• A separate statistical health file, comprising health expenditure, health infrastructure, health services and health personnel.
• The reports are updated quarterly, providing you with the latest information for a full year. In addition, the service will keep you up to date with market and industry news on a regular basis.

A comprehensive tabula review, comprising demographics, epidemiology, health expenditure, hospital and primary care infrastructure & services and healthcare personnel, is additionally included.

• Publication Date: October 31^st 2011
• Total Number of Pages: 66
• Formats: Web, PDF and Paper

EXECUTIVE SUMMARY

• Snapshot: Strategic Espicom Analysis
• Snapshot: Key Data Projections

MACROENVIRONMENT

• POLITICAL
• ECONOMIC
  • Projections
• LEGAL
  • IPR Provisions
  • Developments Related to the United States - Colombia Trade Promotion Agreement
  • Parallel Imports
• DEMOGRAPHIC
  • Projections
  • Latest Figures
  • Demographic Indicators
    • Birth Rate
    • Death Rate
    • Infant Mortality Rate
    • Life Expectancy at Birth

EPIDEMIOLOGY

• DISEASE BURDEN
• DISEASE PREVALENCE
  • Communicable Diseases
    • HIV/AIDS
  • Non-Communicable Diseases

HEALTHCARE - ACCOMPANYING HEALTH STATISTICS

• ORGANISATION
  • Health Insurance
  • Health Reform
• EXPENDITURE
  • Health Expenditure Projections
• INFRASTRUCTURE
  • Hospital Infrastructure
  • Ambulatory Infrastructure
• SERVICES
  • Hospital Activity
  • Ambulatory Activity
• WORKFORCE
  • Projections

REGULATORY AFFAIRS

• PHARMACEUTICAL REGULATION
• PHARMACEUTICAL REGISTRATION
  • New Drugs
  • Modifications
  • Renewals
  • Biologic Products
  • Product Control & Vigilance
  • Import Certification
• PROMOTION

PRICING & REIMBURSEMENT

• PRICING
  • Measures Implemented in 2010
  • Drug Price Deregulation
• REIMBURSEMENT

DISTRIBUTION CHANNELS

• RETAILING
  • Regulation
  • Trade Association
    • ASOCOLDRO
  • Leading Co-operatives/Pharmacy Chains/Cajas
    • Audifarma
    • Colsubsidio
    • COPSERVIR
    • COPIDROGAS
    • EPSIFARMA
    • Éticos Serrano Gómez
    • Farmasánitas

MARKET ANALYSIS

• SIZE
  • Projections
  • Historical Figures
  • Structure
    • Pharmacy Sales
    • Hospital Sales
• PRODUCT DEVELOPMENT
• PRODUCTION
• TRADE
  • Exports
  • Imports
  • Balance of Trade

COMPETITION

• TRADE ASSOCIATIONS
  • AFIDRO
  • ANDI
  • ASINFAR
  • CECIF
• COMPANY INTELLIGENCE
  • Foreign Producers
    • Baxter
    • Bayer Schering Pharma
    • Boehringer Ingelheim
    • Mcneil (Johnson & Johnson)
    • Merck
    • sanofi-aventis
    • Schering Plough (MSD)
  • Local Producers
    • GENFAR
    • JGB
    • LAFRANCOL
    • La Santé
    • Procaps
    • Tecnoquimícas
  • Competitive Strategies

OTC PHARMACEUTICALS

• MARKET ANALYSIS
• COMPETITION

GENERIC PHARMACEUTICALS

• MARKET ANALYSIS
• COMPETITION
  • Trade Associations
    • ANDI
    • ASINFAR

BIOLOGICS & BIOSIMILARS

• REGULATION
• R&D
• COMPETITION
  • Trade Conference/Show
    • CIB

CONCLUSIONS: OPPORTUNITIES & CHALLENGES

• Strategic Espicom Analysis
  • MACROENVIRONMENT
  • EPIDEMIOLOGY
  • HEALTHCARE
  • REGULATORY AFFAIRS
  • PRICING & REIMBURSEMENT
  • DISTRIBUTION CHANNELS
  • MARKET
  • COMPETITION
  • OTC PHARMACEUTICALS
  • GENERIC PHARMACEUTICALS
  • BIOLOGICS & BIOSIMILARS
• Radar Analysis
• SWOT Analysis

DIRECTORY

• COMPANY INTELLIGENCE
  • Foreign Producers
  • Local Producers
• GOVERNMENT ORGANISATIONS
• TRADE ASSOCIATIONS

• Espicom Analysis of the Pharmaceutical Market, 2011
• Key Data Projections, 2011-2016
• Political Landscape, 2011
• Regional Ranking of Projected Economies, 2016
• Projected Economy, 2011-2016
• Regional Ranking of Projected Demographics, 2016
• Projected Demographics, 2011-2016
• Demographic Indicators, 2000-2008
• Main Causes of Death, 2002-2007
• SGSSS Affiliation by Type, 2008-2009
• Regional Ranking of Projected Health Expenditure, 2016
• Projected Health Expenditure, 2011-2016
• Regional Ranking of Projected Physicians, 2016
• Projected Physicians, 2011-2016
• New Drug Pricing Classification by Type, 2005
• New Drug Pricing Classification by Type I, 2005 (%)
• New Drug Pricing Classification by Type II, 2005 (%)
• Leading Pharmaceutical Retailers, 2009/2010 (Million Pesos)
• Regional Ranking of Projected Pharmaceutical Markets at Retail Prices, 2016
• Projected Pharmaceutical Market at Retail Prices, 2011-2016
• Historical Pharmaceutical Market at Retail Prices, 1995-2010
• Pharmacy Sales by Type at Manufacturers' Prices, 2009 (Million Pesos)
• Pharmaceutical Production Indicators, 2000-2007
• Gross Pharmaceutical Production by Category, 2007 (Billion Pesos)
• Pharmaceutical Employment by Category, 2007
• INVIMA-Certified Pharmaceutical Manufacturing Establishments, 15th October 2010
• Pharmaceutical Exports by Category, 2005-2009 (US$000s)
• Pharmaceutical Exports by Country/Region, 2009 (US$000s)
• Pharmaceutical Imports by Category, 2005-2009 (US$000s)
• Imports of Raw Materials by Country/Region, 2009 (US$000s)
• Imports of Antisera & Vaccines by Country/Region, 2009 (US$000s)
• Imports of Medicaments by Country/Region, 2009 (US$000s)
• Pharmaceutical Balance of Trade, 2005-2009 (US$000s)
• Leading Pharmaceutical Companies by Sales, 2009/2010 (Million Pesos)
• Leading Pharmaceutical Companies by Revenues, 2005-2008 (Million Pesos)
• Leading Pharmaceutical Companies by Revenues, 2005-2008 (US$ Million)
• Members of AFIDRO, 2010
• Members of CECIF, 2010
• Espicom Analysis of the Pharmaceutical Market, 2011
• SWOT Analysis of the Pharmaceutical Market, 2011

• Regional Comparison of Top 5-10 Projected Pharmaceutical Markets at Retail Prices, 2016
• Regional Comparison of Projected Pharmaceutical Market Share at Retail Prices, 2016
• Historical Pharmaceutical Market at Retail Prices, 1995-2010
• Pharmaceutical Exports, 2003-2009 (US$ Millions)
• Pharmaceutical Imports, 2003-2009 (US$ Millions)
• Pharmaceutical Imports by Country/Region, 2009 (%)
• Pharmaceutical Balance of Trade, 2003-2009 (US$ Millions)
• Radar Graph of the Pharmaceutical Market, 2011

Related Reports